Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2022-09-14 , DOI: 10.1002/alz.12806
Joel Simrén ₁ , Haley Weninger ₁ , Wagner S Brum _{1,

2} , Shilla Khalil ₁ , Andréa L Benedet ₁ , Kaj Blennow _{1,

3} , Henrik Zetterberg _{1,

3,

4,

5} , Nicholas J Ashton _{1,

6,

7,

8}

Affiliation

Recent evidence has shown that the marker of reactive astrogliosis, glial fibrillary acidic protein (GFAP), has a stronger relationship with cerebral amyloid beta (Aβ) pathology in blood than in cerebrospinal fluid (CSF). This study investigates if pre-analytical treatment of blood and CSF contribute to these unexpected findings.

中文翻译：